AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics‘ Libmeldy, which was recently approved by the European Commission as a one-time therapy for early-onset Metachromatic Leukodystrophy (MLD), a rare neurodegenerative disorder caused by mutations in the ARSA gene.   Libmeldy (autologous CD34+ cells encoding the ARSA gene), is a lentiviral vector-based gene therapy manufactured at AGC Biologics&#82...